EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Adaptimmune Therapeutics's enterprise value is $174.75 Mil.
Adaptimmune Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-128.20 Mil. Therefore, Adaptimmune Therapeutics's EV-to-EBITDA for today is -1.36.
The historical rank and industry rank for Adaptimmune Therapeutics's EV-to-EBITDA or its related term are showing as below:
ADAP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1536.13 Med: -3.13 Max: 0.42
Current: -1.36
During the past 12 years, the highest EV-to-EBITDA of Adaptimmune Therapeutics was 0.42. The lowest was -1536.13. And the median was -3.13.
ADAP's EV-to-EBITDA is ranked worse than 100% of 464
companies
in the Biotechnology industry
Industry Median: 9.94
vs ADAP: -1.36
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-16), Adaptimmune Therapeutics's stock price is $1.06.
Adaptimmune Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.474. Therefore, Adaptimmune Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Adaptimmune Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Adaptimmune Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Adaptimmune Therapeutics Annual Data
Trend
Jun14
Jun15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
EV-to-EBITDA
-0.47
-3.89
-1.55
-0.38
-0.46
Adaptimmune Therapeutics Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
EV-to-EBITDA
-0.38
-0.37
-0.29
-0.39
-0.46
Competitive Comparison
For the Biotechnology subindustry, Adaptimmune Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adaptimmune Therapeutics EV-to-EBITDA Distribution
For the Biotechnology industry and Healthcare sector, Adaptimmune Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Adaptimmune Therapeutics's EV-to-EBITDA falls into.
Adaptimmune Therapeutics EV-to-EBITDA Calculation
Adaptimmune Therapeutics's EV-to-EBITDA for today is calculated as:
Adaptimmune Therapeutics's current Enterprise Value is $174.75 Mil.
Adaptimmune Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-128.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Adaptimmune Therapeutics's PE Ratio for today is calculated as:
Adaptimmune Therapeutics's share price for today is $1.06.
Adaptimmune Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.474.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Adaptimmune Therapeutics EV-to-EBITDA Related Terms
Thank you for viewing the detailed overview of Adaptimmune Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Adaptimmune Therapeutics (Adaptimmune Therapeutics) Business Description
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADAP has been successfully added to your 